Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST11 vascular targeted photodynamic therapy for T1a renal tumours
2011-003311-27Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Sep 2012
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padeliporfin VTP in renal cell carcinoma (RCC), sponsored by University of Oxford. Primary endpoint: Volume of tumour necrosis on final histology. Started Sep 2012; status: terminated.
02
Drugs
padeliporfin VTP
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2011-003311-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003311-27.